-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $15

Benzinga·08/11/2026 13:51:58
Listen to the news
Wedbush analyst Yun Zhong maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $16 to $15.